|Slideshows|September 20, 2019

9 high-risk situations for wandering and elopement

Author(s)Jonna L Gattuso, PsyD, Alix McNulty, MSN, BA, RN, CPSTI, Sarah C Bauer, MD, MS

Elopement and wandering are serious problems for families of children with autism spectrum disorder (ASD). Here are 9 high-risk situations when parents and caregivers need to be more mindful.

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Subscribe Now!

Related Content

FDA expands antithrombin III (human) label to pediatric patients with rare blood-clotting disorder

ByJoshua Fitch, Senior Editor

November 18th 2025

Olivia Kim-McManus, MD, discusses genetic testing, therapy in pediatric neurology

ByOlivia Kim-McManus, MD

November 17th 2025

FDA accepts roflumilast cream 0.3% sNDA to treat plaque psoriasis in children 2 to 5 years

ByJoshua Fitch, Senior Editor

November 17th 2025

Long-term outcomes of lentiviral gene therapy for ADA-deficient severe combined immunodeficiency

ByMorgan Ebert, Managing Editor

November 16th 2025

Study: Child maltreatment rates declined overall, but disparities persisted across sex and race

ByMorgan Ebert, Managing Editor

November 15th 2025

Latest CME

Video

Clinical Consultations™: Addressing Elevated Phosphate Levels in Patients with END-STAGE Kidney Disease (ESKD)

Anil K. Agarwal, MD, FACP, FASN, FNKF, FASDIN; Jay B. Wish, MD

Multimedia

Advances In: Managing Hyperphosphatemia in Chronic Kidney Disease – Bridging Treatment Gaps With Novel Therapies

Glenn M. Chertow, MD, MPH; Anjay Rastogi, MD, PhD

Case-based Simulation

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Nicholas Doher, DO; Babak Tousi, MD

Multimedia

Burst CME™: Addressing Inadequate Response to Anti-TNF Therapy in Patients With Rheumatoid Arthritis

Jeffrey A. Sparks, MD, MMSc

Multimedia

Community Practice Connections™: Cases and Conversations – Keeping Up with Novel Approaches to Managing ANCA-Associated Vasculitis

Frank B. Cortazar, MD; Lindsay S. Lally, MD

Video

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Tina Bhutani, MD

Video

Cases and Conversations™: A Horizon View of Continuous Monitoring Systems for Diabetes Management

Diana Isaacs, PharmD, BCPS, BC-ADM, BCACP, CDCES, FADCES, FCCP; Anders Carlson, MD; Jennifer B. Green, MD

Video

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Nihar R. Desai, MD, MPH; Martha Gulati, MD, MS, FACC, FAHA, MASPC, FESC, FSCCT (hon), FRCP Edin

9 high-risk situations for wandering and elopement

Newsletter

Related Content

FDA expands antithrombin III (human) label to pediatric patients with rare blood-clotting disorder

Olivia Kim-McManus, MD, discusses genetic testing, therapy in pediatric neurology

FDA accepts roflumilast cream 0.3% sNDA to treat plaque psoriasis in children 2 to 5 years

Long-term outcomes of lentiviral gene therapy for ADA-deficient severe combined immunodeficiency

Study: Child maltreatment rates declined overall, but disparities persisted across sex and race

Latest CME

Clinical Consultations™: Addressing Elevated Phosphate Levels in Patients with END-STAGE Kidney Disease (ESKD)

Advances In: Managing Hyperphosphatemia in Chronic Kidney Disease – Bridging Treatment Gaps With Novel Therapies

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Burst CME™: Addressing Inadequate Response to Anti-TNF Therapy in Patients With Rheumatoid Arthritis

Community Practice Connections™: Cases and Conversations – Keeping Up with Novel Approaches to Managing ANCA-Associated Vasculitis

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Cases and Conversations™: A Horizon View of Continuous Monitoring Systems for Diabetes Management

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Trending on Contemporary Pediatrics

Olivia Kim-McManus, MD, discusses genetic testing, therapy in pediatric neurology

FDA expands antithrombin III (human) label to pediatric patients with rare blood-clotting disorder

FDA accepts roflumilast cream 0.3% sNDA to treat plaque psoriasis in children 2 to 5 years

Roflumilast Efficacy and Safety in Pediatric AD

Systemic Absorption and Dosing in Pediatric AD